Aerie Pharmaceuticals reported $311.68M in Loan Capital for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Loan Capital Change
Aerie Pharmaceuticals AERI:US $ 311.68M 77.15M
Alimera Sciences ALIM:US $ 36.24M 6.84M
Amarin AMRN:US $ 0M 0M
Bluebird Bio BLUE:US $ 0M 0M
Cara Therapeutics CARA:US $ 0 0
Coherus Biosciences CHRS:US $ 420.46M 11.68M
Endo International Ordinary Shares ENDP:US $ 8057.5M 9.85M
Horizon Pharma HZNP:US $ 2552.74M 2.49M
Insmed INSM:US $ 806.66M 225.97M
JAZZ PHA JAZZ:US $ 5992.87M 32.34M
Merk MRK:US $ 30586M 104M
Mirati Therapeutics MRTX:US $ 0M 0M
Novartis NOVN:VX SF 24373M 150M
Ophthotech OPHT:US $ 0M 0M
Pacira Pharmaceuticals PCRX:US $ 729.74M 55.21M
Regeneron Pharmaceuticals REGN:US $ 2700.4M 720.4M
Revance Therapeutics RVNC:US $ 430.86M 150.23M
Supernus Pharmaceuticals SUPN:US $ 400.38M 21.13M
Teva Pharmaceutical Industries TEVA:US $ 20840M 777M
Valeant Pharmaceuticals VRX:CN $ 23168M 514M
Zoetis ZTS:US $ 5228M 1364M